JP2025510556A - アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター - Google Patents

アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター Download PDF

Info

Publication number
JP2025510556A
JP2025510556A JP2024552684A JP2024552684A JP2025510556A JP 2025510556 A JP2025510556 A JP 2025510556A JP 2024552684 A JP2024552684 A JP 2024552684A JP 2024552684 A JP2024552684 A JP 2024552684A JP 2025510556 A JP2025510556 A JP 2025510556A
Authority
JP
Japan
Prior art keywords
s1pr
modulator
dementia
alzheimer
fingolimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510556A5 (enExample
Inventor
レスマン，フォルクマー
ゴットマン，クルト
エンドレス，トーマス
カータルー，ジョージア－イオアナ
Original Assignee
オットー－フォン－ゲーリケ－ウニヴェルズィテート マクデブルク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オットー－フォン－ゲーリケ－ウニヴェルズィテート マクデブルク filed Critical オットー－フォン－ゲーリケ－ウニヴェルズィテート マクデブルク
Publication of JP2025510556A publication Critical patent/JP2025510556A/ja
Publication of JP2025510556A5 publication Critical patent/JP2025510556A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024552684A 2022-03-31 2023-03-30 アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター Pending JP2025510556A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166162.2A EP4252748A1 (en) 2022-03-31 2022-03-31 A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia
EP22166162.2 2022-03-31
PCT/EP2023/058360 WO2023187091A1 (en) 2022-03-31 2023-03-30 A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia

Publications (2)

Publication Number Publication Date
JP2025510556A true JP2025510556A (ja) 2025-04-15
JP2025510556A5 JP2025510556A5 (enExample) 2025-10-24

Family

ID=81325093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552684A Pending JP2025510556A (ja) 2022-03-31 2023-03-30 アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター

Country Status (5)

Country Link
US (1) US20250325501A1 (enExample)
EP (2) EP4252748A1 (enExample)
JP (1) JP2025510556A (enExample)
CA (1) CA3250398A1 (enExample)
WO (1) WO2023187091A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010110440A1 (ja) * 2009-03-26 2010-09-30 大日本住友製薬株式会社 新規認知機能障害治療剤
JP2014513694A (ja) * 2011-05-09 2014-06-05 イーアイピー ファーマ， エルエルシー アルツハイマー病を処置するための組成物および方法
WO2016044103A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
WO2018208855A1 (en) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
JP2021528442A (ja) * 2018-06-19 2021-10-21 ウニベルシダ パブロ デ オラビデ タンパク質凝集性疾患を治療及び／又は予防するための組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010110440A1 (ja) * 2009-03-26 2010-09-30 大日本住友製薬株式会社 新規認知機能障害治療剤
JP2014513694A (ja) * 2011-05-09 2014-06-05 イーアイピー ファーマ， エルエルシー アルツハイマー病を処置するための組成物および方法
WO2016044103A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
WO2018208855A1 (en) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
JP2021528442A (ja) * 2018-06-19 2021-10-21 ウニベルシダ パブロ デ オラビデ タンパク質凝集性疾患を治療及び／又は予防するための組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGELOPOULOU, EFTHALIA ET AL.: ""Beneficial Effects of Fingolimod in Alzheimer’s Disease: Molecular Mechanisms and Therapeutic Pot", NEUROMOLECULAR MEDICINE, vol. 21, no. 3, JPN6025044611, 2019, pages 227 - 238, ISSN: 0005841832 *
ASLE-ROUSTA, M. ET AL.: ""ACTIVATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR-1 BY SEW2871 IMPROVES COGNITIVE FUNCTION IN ALZHEIM", EXCLI JOURNAL, vol. 12, JPN6025044610, 2013, pages 449 - 461, ISSN: 0005841831 *
YUAN, YUAN ET AL.: ""Structures of signaling complexes of lipid receptors S1PR1 and S1PR5 reveal mechanisms of activati", CELL RESEARCH, vol. 31, no. 12, JPN6025044609, 2021, pages 1263 - 1274, ISSN: 0005841830 *

Also Published As

Publication number Publication date
EP4252748A1 (en) 2023-10-04
US20250325501A1 (en) 2025-10-23
EP4499056A1 (en) 2025-02-05
WO2023187091A1 (en) 2023-10-05
CA3250398A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
CN104127434B (zh) 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
US20200375966A1 (en) Use of pridopidine for the treatment of anxiety and depression
KR20150002681A (ko) App 특이적 bace 억제제(asbi) 및 이의 용도
JP2020514313A (ja) 脆弱ｘ症候群の治療のためのプリドピジンの使用
JP2018526407A (ja) 特定の患者集団において神経変性障害を処置する方法
US20240277732A1 (en) Compositions and methods for treating brain-gut disorders
CN105517546A (zh) 治疗脆性x综合征及相关疾病的方法
JP7737721B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP2010530371A (ja) 神経学的機能を増強するための作用物質、組成物および方法
JP2025163203A (ja) ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
US20220105106A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
AU2019229892A1 (en) Treatment of demyelinating diseases
EP3455223A1 (en) Compounds to promote normal processing of app
JP6830895B2 (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
JP7766026B2 (ja) 自閉症スペクトラム障害の症状を治療する方法
JP2025510556A (ja) アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
JP2019521117A (ja) 中枢神経系障害の治療のための安息香酸リチウムの使用
Yaari et al. Cognitive enhancers and treatments for Alzheimer's disease
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
AU2024244089A1 (en) Methods of dosing spinogenic compounds
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
US20230310447A1 (en) Methods of treating age-related cognitive decline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251016

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260417